US 12109272
Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers
granted A61KA61K31/337A61K31/4745
Quick answer
US patent 12109272 (Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers) held by Corcept Therapeutics Incorporated expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Corcept Therapeutics Incorporated
- Grant date
- Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K31/337, A61K31/4745, A61K47/643, A61P